Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Gilead Sciences, Inc. (NASDAQ: GILD).

Full DD Report for GILD

You must become a subscriber to view this report.


Recent News from (NASDAQ: GILD)

Your Daily Pharma Scoop: Biohaven Updates, MEIP Offering, Kite European Expansions
Analysis focus: BHVN Biohaven Pharmaceuticals (BHVN) is a CNS-focused company with a strong pipeline with multiple drug candidates in late stage trials. The company recently announced a number of updates for its pipeline. For its lead candidate, rimegepant from the CGRP receptor antagoni...
Source: SeekingAlpha
Date: May, 17 2018 00:16
Gilead Sciences (GILD) Presents at the Bank of America Merrill Lynch 2018 Healthcare Conference (Transcript)
Gilead Sciences, Inc. (GILD) Bank of America Merrill Lynch 2018 Healthcare Conference May 17, 2018 12:20 PM ET Executives Robin Washington - CFO John McHutchison - Chief Scientific Officer Analysts Ying Huang - Bank of America Merrill Lynch Presentation Ying Huang ...
Source: SeekingAlpha
Date: May, 16 2018 18:41
Biotechs perk up ahead of ASCO abstract drop
The SPDR S&P Biotech ETF ( XBI +1.1% ) is up  1%  as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He...
Source: SeekingAlpha
Date: May, 16 2018 12:56
Bluebird Bio: Gene Therapy Best In Class
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two...
Source: SeekingAlpha
Date: May, 16 2018 11:31
Bellicum Pharmaceuticals: Will This CAR-TCR Innovator Deliver Robust Profits?
Bellicum Pharmaceuticals (NASDAQ: BLCM ) is a stellar therapeutic innovator that has experienced a share price depreciation for the past year. Nevertheless, the company is powering the robust development of a highly advanced chimeric antigen receptor and T-cell receptor (CAR-TCR) that, in an...
Source: SeekingAlpha
Date: May, 16 2018 06:55
5 Low P/E Companies In The S&P 500 - May 2018
There are a number of great companies in the market today. By using the ModernGraham Valuation Model , I've selected some of the most undervalued companies of S&P 500. The ModernGraham model is based on the full teachings of Benjamin Graham. All of these companies are suitable for the De...
Source: SeekingAlpha
Date: May, 15 2018 15:52
Gilead Sciences: Resist Sentiment, Stop Speculating And Invest
After a few months of rather positive signs and slight increase in bullishness, bearish sentiment seems to be back. In 2016 and 2017 Wall Street almost begged for an acquisition and when Gilead Sciences (Nasdaq: GILD ) finally announced the take-over of Kite Pharma, sentiment became more posi...
Source: SeekingAlpha
Date: May, 15 2018 14:07
U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
– First Agent Indicated for Uninfected Adolescents at Risk of Acquiring HIV – Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada ® (emtricitabine 200 mg/tenofovir disoproxil fu...
Source: Business Wire
Date: May, 15 2018 10:59
Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline
-- Facilities in the Netherlands and the United States Will Help Advance Manufacturing of Cell Therapies for People with Cancer -- Kite, a Gilead Company (Nasdaq: GILD), today announced it has leased a new facility in the Netherlands to engineer cell therapies in Europe. The 117,000...
Source: Business Wire
Date: May, 15 2018 08:30
Genomic Medicine: Catch The Gene Therapy Wave
Genomic medicine is the future of healthcare. Spawned by the Human Genome Project “HGP” this precise and personal approach to medicine is an emerging discipline with enormous disruptive potential. Though nascent, Genomic medicine is showing signs of being the transformative for...
Source: SeekingAlpha
Date: May, 14 2018 15:12

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1767.1067.6068.129967.105,946,194
2017-06-1365.6165.1565.6565.018,185,266
2017-06-1264.6065.4366.7064.5510,459,196
2017-06-0964.1164.7064.9463.959,338,911
2017-06-0864.1664.1264.5864.0558,744,915

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-13141,762704,66920.1175Cover
2018-08-10214,6171,087,90419.7276Cover
2018-08-09307,4111,284,28523.9364Cover
2018-08-08203,185878,49523.1288Cover
2018-08-07226,820920,39224.6438Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GILD.


About Gilead Sciences, Inc. (NASDAQ: GILD)

Logo for Gilead Sciences, Inc. (NASDAQ: GILD)

Not available

 

Contact Information

 

 

Current Management

  • John C. Martin / President, CEO
  • John F. Milligan / CFO, COO

Current Share Structure

  • Market Cap: $87,832,619,202 - 05/16/2018
  • Issue and Outstanding: 1,300,260,832 - 04/30/2018

 


Recent Filings from (NASDAQ: GILD)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 26 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 08 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 27 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: February, 27 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: February, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 09 2018

 

 


Daily Technical Chart for (NASDAQ: GILD)

Daily Technical Chart for (NASDAQ: GILD)


Stay tuned for daily updates and more on (NASDAQ: GILD)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: GILD)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GILD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of GILD and does not buy, sell, or trade any shares of GILD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/